Company Lucy Scientific Discovery Inc.

LSDI

CA54960E2033

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.7597 ^USD	-12.68%		-32.17%	-70.33%

Mar. 06	Lucy Scientific Discovery Inc. cancelled the acquisition of BlueSky Wellness Inc.	CI
Feb. 27	Lucy Scientific Discovery Inc. Announces Expiration of Term Assad J. Kazeminy, Chief Scientific Officer	CI

Lucy Scientific Discovery Inc. is an early stage psychotropics contract manufacturing company. The Company is engaged in researching, developing, and manufacturing psychotropic drugs. The Company is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. It is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The Company is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.

Number of employees: 2

USD in Million	2022	Weight	2023	Weight	Delta
Psychedelic Products 100.0 %	0	nan %	0	100.0 %	-

USD in Million	2022	Weight	2023	Weight	Delta
Canada 100.0 %	0	nan %	0	100.0 %	-

Managers	Title	Age	Since
Richard Nanula CEO	Chief Executive Officer	63	22-01-31
Brian Zasitko DFI	Director of Finance/CFO	44	21-10-31
Assad Kazeminy CTO	Chief Tech/Sci/R&D Officer	73	21-01-31
Scott Reeves BRD	Director/Board Member	55	19-09-30

Members of the board	Title	Age	Since
Richard Nanula CEO	Chief Executive Officer	63	22-01-31
Charles Nemeroff BRD	Director/Board Member	74	21-10-31
Livio Susin BRD	Director/Board Member	69	17-08-31
Scott Reeves BRD	Director/Board Member	55	19-09-30
Paul Abramowitz BRD	Director/Board Member	68	21-10-31
Brittany Kaiser BRD	Director/Board Member	35	21-10-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,764,755	1,228,517 ( 69.61 %)	0	69.61 %

Name	Equities	%	Valuation
Christopher McElvany 9.422 %	166,283	9.422 %	231 466 $
Roma Ventures LLC 5.560 %	98,118	5.560 %	136 580 $
Renee Gagnon 5.375 %	94,853	5.375 %	132 035 $
AdvisorShares Investments LLC 5.000 %	88,230	5.000 %	122 816 $
Roxy Capital, Inc. 4.571 %	80,665	4.571 %	112 286 $
Dpl Capital, Inc. 4.482 %	79,101	4.482 %	110 109 $
Henry Chamberlain 4.269 %	75,334	4.269 %	104 865 $
The K2 Principal Fund LP 1.417 %	25,000	1.417 %	34 800 $
Richard Nanula 0.9476 %	16,722	0.9476 %	23 277 $
Livio Susin 0.7859 %	13,870	0.7859 %	19 307 $

Lucy Scientific Discovery, Inc.

1321 Blanshard Street Suite 301

V8W 0B6, Victoria

http://www.lucyscientific.com

address Lucy Scientific Discovery Inc.(LSDI)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
LUCY SCIENTIFIC DISCOVERY INC.	-70.33%	1.34M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals